Exact Sciences Management
Management criteria checks 2/4
Exact Sciences' CEO is Kevin Conroy, appointed in Apr 2009, has a tenure of 15.58 years. total yearly compensation is $16.12M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.38% of the company’s shares, worth $36.25M. The average tenure of the management team and the board of directors is 3.8 years and 5.7 years respectively.
Key information
Kevin Conroy
Chief executive officer
US$16.1m
Total compensation
| CEO salary percentage | 6.5% |
| CEO tenure | 15.6yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.8yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge
Nov 10
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Sep 25Exact Sciences: Cost Optimization And Product Strength
Aug 18Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Aug 14Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$214m |
| Jun 30 2024 | n/a | n/a | -US$175m |
| Mar 31 2024 | n/a | n/a | -US$240m |
| Dec 31 2023 | US$16m | US$1m | -US$204m |
| Sep 30 2023 | n/a | n/a | -US$282m |
| Jun 30 2023 | n/a | n/a | -US$432m |
| Mar 31 2023 | n/a | n/a | -US$517m |
| Dec 31 2022 | US$14m | US$510k | -US$624m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$735m |
| Mar 31 2022 | n/a | n/a | -US$745m |
| Dec 31 2021 | US$15m | US$963k | -US$596m |
| Sep 30 2021 | n/a | n/a | -US$793m |
| Jun 30 2021 | n/a | n/a | -US$829m |
| Mar 31 2021 | n/a | n/a | -US$720m |
| Dec 31 2020 | US$20m | US$499k | -US$824m |
| Sep 30 2020 | n/a | n/a | -US$327m |
| Jun 30 2020 | n/a | n/a | -US$165m |
| Mar 31 2020 | n/a | n/a | -US$136m |
| Dec 31 2019 | US$19m | US$792k | -US$213m |
| Sep 30 2019 | n/a | n/a | -US$216m |
| Jun 30 2019 | n/a | n/a | -US$221m |
| Mar 31 2019 | n/a | n/a | -US$219m |
| Dec 31 2018 | US$7m | US$696k | -US$175m |
| Sep 30 2018 | n/a | n/a | -US$143m |
| Jun 30 2018 | n/a | n/a | -US$124m |
| Mar 31 2018 | n/a | n/a | -US$119m |
| Dec 31 2017 | US$13m | US$633k | -US$114m |
Compensation vs Market: Kevin's total compensation ($USD16.12M) is above average for companies of similar size in the US market ($USD7.84M).
Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.
CEO
Kevin Conroy (58 yo)
15.6yrs
Tenure
US$16,119,899
Compensation
Mr. Kevin T. Conroy served as Independent Director of SomaLogic, Inc. since September 1, 2021, until January 2022. Mr. Conroy had served as an Independent Director of Adaptive Biotechnologies Corporation s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of The Board & CEO | 15.6yrs | US$16.12m | 0.38% $ 36.2m | |
| Executive VP & GM of Screening | no data | US$3.67m | 0.0084% $ 792.7k | |
| Executive VP & General Manager of Precision Oncology | no data | US$3.57m | 0.0071% $ 673.0k | |
| Executive Vice President of Finance | less than a year | no data | no data | |
| Chief Science Officer | 3.6yrs | no data | no data | |
| Chief Information Officer | 1.8yrs | no data | no data | |
| Associate Manager of Investor Relations | no data | no data | no data | |
| Chief Compliance Counsel & VP | 9.8yrs | no data | no data | |
| Senior VP | 2.8yrs | no data | 0.0060% $ 562.7k | |
| Executive Vice President of Human Resources | 7.5yrs | US$2.71m | 0.042% $ 4.0m | |
| Emeritus Chief Science Officer | 3.8yrs | US$4.21m | no data | |
| Chief Laboratory Officer | 9.3yrs | US$3.95m | no data |
3.8yrs
Average Tenure
50yo
Average Age
Experienced Management: EXAS's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of The Board & CEO | 15.7yrs | US$16.12m | 0.38% $ 36.2m | |
| Independent Director | 14.3yrs | US$408.75k | 0.015% $ 1.4m | |
| Director | 1.9yrs | US$1.47m | 0.030% $ 2.8m | |
| Independent Director | 15.6yrs | US$406.25k | 0.038% $ 3.6m | |
| Independent Director | less than a year | no data | 0.0029% $ 277.1k | |
| Independent Director | 3.7yrs | US$417.75k | 0.011% $ 1.0m | |
| Independent Director | 5.7yrs | US$411.75k | 0.017% $ 1.6m | |
| Independent Director | 4.3yrs | US$401.25k | 0.012% $ 1.2m | |
| Lead Independent Director | 10.3yrs | US$442.75k | 0.030% $ 2.8m |
5.7yrs
Average Tenure
63yo
Average Age
Experienced Board: EXAS's board of directors are considered experienced (5.7 years average tenure).